University of Leicester researcher in potential medical breakthrough
“This new drug could be a game changer for future treatment of asthma” – Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester
The first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.
The research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as “a game changer for future treatment of asthma.”
Three people die every day because of asthma attacks and research shows that two thirds of asthma deaths are preventable, according to Asthma UK.
Fevipiprant (QAW039) significantly decreased the symptoms of asthma, improved lung function, reduced inflammation and repaired the lining of airways.
The drug is currently being evaluated in late stage clinical trials for efficacy in patients with severe asthma, according to ClinTrials.gov.
A total of 61 people took part in the research. One group was given 225mg of the drug twice a day for 12 weeks and the other participants were assigned to a placebo group. Fevipiprant and the placebo were added to the medications the participants were already taking.
The study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.
The sputum eosinophil is an inflammation measurement of a white blood cell that increases in asthma and is used to assess the severity of this condition.
People who do not have asthma have a percentage of less than one and those with moderate-to-severe asthma typically have a reading of about five per cent.
The rate in people with moderate-to-severe asthma taking the medication was reduced from an average of 5.4 percent to 1.1 percent over 12 weeks, according to the study published today in the prestigious The Lancet Respiratory Medicine journal.
Professor Christopher Brightling, who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.
Professor Brightling said: “A unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works.
“Most treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all of the types of tests.
“We already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.
“This new treatment, Fevipiprant, could likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms- making it a ‘game changer’ for future treatment.”
Gaye Stokes from Grantham in Lincolnshire has had severe asthma for 16 years. She took part in the trial and was part of the Fevipiprant group.
The 54-year-old said: “I knew straight away that I had been given the drug. I felt like a completely different person. I had more get up and go, I was less wheezy and for the first time in years I felt really, really well.
“For me, it felt like a complete wonder drug and I can’t wait for it to be available because I really think it could make a huge difference to me.”
After the 12 week trial and Gaye stopped receiving the drug, she said her health started to “go downhill again very quickly”.
Professor Brightling added that the latest advance underpinned the work of the Leicester Precision Medicine Institute, a Centre of Excellence that coalesces and aligns the research missions of the University of Leicester and the NHS in Leicester.
Future treatment of human disease will increasingly move from a ‘one size fits all’ approach to one of tailoring the treatment to the individual patient.
Asthma is a long-term condition that affects the airways. When a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.
The NIHR Leicester Respiratory Biomedical Research Unit – a partnership between the University of Leicester and Leicester’s Hospitals – focuses on promoting the development of new and effective therapies for the treatment of respiratory diseases including severe asthma and chronic obstructive pulmonary disease (COPD).
The Latest on: Asthma pill
via Google News
The Latest on: Asthma pill
- Kinaset Therapeutics debuts with $40M for pan-JAK asthma medon November 30, 2020 at 3:00 am
There is a host of treatments for people with asthma, from inhaled and oral corticosteroids to newer injected biologics. But these drugs don’t work for everyone, since different factors cause asthma ...
- ACT Health warns of thunderstorm asthma eventon November 29, 2020 at 9:30 pm
ACT Health warns there may be a thunderstorm asthma event on December 1 due to elevated pollen levels and the risk of severe thunderstorms in the region. While not all thunderstorms create asthma ...
- Behavior Intervention Can Increase Physical Activity and Improve Asthma Controlon November 25, 2020 at 6:56 am
Patients with asthma can improve their disease control and sleep quality, while reducing depression and anxiety through a behavior change intervention aimed at increasing their physical activity.
- Birth control pills may reduce severe asthma risk: Studyon November 24, 2020 at 1:06 pm
Taking birth control pills may cut the risk of severe bouts of asthma in women of reproductive age with the respiratory condition, say researchers. The findings, published in the journal Thorax, ...
- Could the Pill Reduce Asthma Attacks?on November 24, 2020 at 11:17 am
Women with asthma may suffer fewer severe symptom attacks if they are on birth control pills, a large new study suggests.
- Taking the Pill may cut risk of severe asthma bouts in women of reproductive ageon November 23, 2020 at 3:32 pm
Taking the Pill may cut the risk of severe bouts of asthma in women of reproductive age with the respiratory condition, finds a large long term study published online in the journal Thorax.
- Implementing Certain Asthma Interventions Could Reduce Health Spending, Utilizationon November 19, 2020 at 4:08 pm
A study looked at how 4 types of interventions for children with asthma could impact expenditures and utilization among Medicaid programs.
- Study: Asthma Patients Maintain High Medication Adherence Using Propeller Health’s Platformon November 19, 2020 at 2:23 pm
Propeller and NorthShore study shows that asthma patients maintain higher medication adherence and decrease their rescue inhaler use.
- Are Doctors Doing Enough to Manage Bone Risks for People With Asthma Who Take Steroids?on November 18, 2020 at 2:11 pm
New data shows that the risk of osteoporosis and fractures is heightened in people with asthma who take both oral and inhaled steroid medications.
- DUPIXENT® (dupilumab injection) now approved by Health Canada for patients with severe asthmaon November 17, 2020 at 4:27 am
Only biologic approved in Canada to treat severe asthma with type 2 / eosinophilic phenotype, or oral corticosteroid-dependent asthma Fourth ...
via Bing News